Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $52.70M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
CLNN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Clene Inc.NASDAQ: CLNN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.31M fell 32.6% year over year, behind the -5.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 57.2% from the prior quarter. Over 3 fiscal years it compounded at -9.2% a year.
Context
- Stock-based compensation amounted to 3191.0% of revenue in FY2025, up 865.6 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -32.6% toward the trailing-twelve-month pace of -5.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.38M USD
- Year-over-year change
- -19.8%
- 4-year CAGR
- -15.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.38M | -19.8% |
| FY2024 | 2024-12-31 | 7.95M | -12.8% |
| FY2023 | 2023-12-31 | 9.12M | +7.1% |
| FY2022 | 2022-12-31 | 8.51M | -31.3% |
| FY2021 | 2021-12-31 | 12.38M | — |
Stock-Based Compensation vs competitors
How CLNN compares with its peers on the latest reported figures
- CLNN's LTM Mar 2026 stock-based compensation of $7.45M is the 6th largest of the 11 companies compared; the peer median is $6.55M.
- Its year-over-year change of -5.5% is the 4th highest of 11, against a peer median of -10.7%.
- Stock-based compensation amounts to 5559.7% of revenue for CLNN, versus a peer median of 103.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.58M | -41.5% | +5.1% | — | |
| LTM Mar 2026 | $14.24M | -76.6% | -23.8% | — | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $9.87M | -8.9% | +0.8% | 138.2% |
| LTM Mar 2026 | $7.69M | -12.5% | +2.7% | 768.9% | |
| LTM Mar 2026 | $7.45M | -5.5% | -9.2% | 5559.7% | |
| LTM Mar 2026 | $5.41M | +63.4% | +174.5% | 68.1% | |
| FY2025 | $3.73M | -44.6% | +54.6% | 5821.9% | |
| LTM Mar 2026 | $2.41M | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $2.28M | +4.3% | — | — | |
| LTM Mar 2026 | $1.45M | +61.5% | +10.9% | — | |
| Peer median (excluding CLNN) | $6.55M | -10.7% | +2.7% | 103.1% | |
Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.74M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Depreciation & Amortization | 955K | 1.02M | 1.71M | 1.65M | 1.5M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.38M | 8.51M | 9.12M | 7.95M | 6.38M |
| Change in Working Capital | 1M | (1.54M) | (191K) | 3.21M | (3.35M) |
| Accounts Receivables | (28K) | (140K) | 46K | 79K | 64K |
| Inventory | 150K | (2K) | 6K | (31K) | 31K |
| Accounts Payables | 1.27M | 285K | (1.51M) | (264K) | (348K) |
| Other Working Capital | (386K) | (1.68M) | 1.27M | 3.43M | (3.1M) |
| Other Non-Cash Items | (39.23M) | (17.09M) | 8.7M | 5.27M | 3.1M |
| Operating Cash Flow | (34.62M) | (39.01M) | (30.17M) | (21.33M) | (18.55M) |
| Capital Expenditures | (1.33M) | (5.18M) | (330K) | (15K) | (39K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (24.61M) | (6.17M) | (6.17M) | 0 |
| Sales of Investments | 0 | 19.63M | 5M | 12.5M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.33M) | (10.16M) | (1.5M) | 6.32M | (39K) |
| Debt Repayment | 19.84M | 5.56M | 269K | (10.9M) | 1.12M |
| Common Stock Issued | 9.25M | 11.46M | 42.09M | 9.24M | 10.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.98M) | 229K | (200K) | 124K | 0 |
| Financing Cash Flow | 27.11M | 17.25M | 42.16M | (1.53M) | 11.52M |
| Effect of Forex Changes | (85K) | (30K) | (4K) | (127K) | 101K |
| Net Change in Cash | (8.93M) | (31.96M) | 10.49M | (16.67M) | (6.97M) |
| Free Cash Flow | (35.96M) | (44.19M) | (30.5M) | (21.34M) | (18.59M) |
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.